在免疫检查点抑制剂巩固治疗时代,心脏辐射剂量与局部晚期非小细胞肺癌患者较差生存相关,但与心脏事件无关
本单机构多中心回顾性研究纳入2017年10月至2021年12月接受根治性同步放化疗的335例局部晚期非小细胞肺癌患者,所有患者均评估免疫检查点抑制剂巩固治疗。中位随访3.3年,未发现任何心脏剂量学参数与主要不良心脏事件或≥3级心脏事件风险增加相关;多变量分析显示左前降支V15Gy及心脏平均剂量与更差的总生存相关,该关联由肺癌特异性死亡驱动而非其他原因死亡。
要点
- 心脏剂量学参数与主要不良心脏事件及≥3级心脏事件风险增加无关。
- 左前降支V15Gy和心脏平均剂量与更差的总生存相关。
- 心脏剂量与肺癌特异性死亡相关,但与其他原因死亡无关。
核心结论
- 在现代放疗技术、更严格的心脏剂量约束和免疫检查点抑制剂巩固治疗下,心脏剂量与局部晚期非小细胞肺癌患者的肺癌特异性死亡相关,但与心脏事件或其他原因死亡无关。
研究设计与样本
- 单机构多中心回顾性研究,纳入2017年10月至2021年12月接受根治性同步放化疗的335例局部晚期非小细胞肺癌患者,所有患者均评估免疫检查点抑制剂巩固治疗。
主要发现
- 中位年龄68岁,139例(41%)有基线冠心病,225例(67%)接受免疫检查点抑制剂巩固治疗。
- 质子治疗117例(35%),调强放疗199例(59%)。
- 左前降支V15Gy中位值为1.4%(IQR 0-22),心脏平均剂量中位值为8.7 Gy(IQR 4.6-14.4)。
- 中位随访3.3年,所有患者2年主要不良心脏事件累积发生率为9.5%,有基线冠心病者为14.3%;2年≥3级心脏事件累积发生率为20.4%。
- 未发现任何心脏剂量学参数与主要不良心脏事件或≥3级心脏事件风险增加相关;多变量分析显示左前降支V15Gy和心脏平均剂量与更差的总生存相关,该关联由肺癌特异性死亡驱动而非其他原因死亡。
关键数值与推荐
- 计划剂量约束包括心脏平均剂量<20 Gy(如可行<10 Gy)和心脏V50Gy<25%。
- 提取了心脏、左前降支冠状动脉和左心室3个心脏结构的21个剂量学参数。
- 主要终点为放化疗后主要不良心脏事件,定义为急性冠脉综合征、心力衰竭、冠状动脉血运重建或心脏相关死亡。
- 次要终点为≥3级心脏事件(按CTCAE v5.0)、总生存、肺癌特异性死亡和其他原因死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed the association of cardiac radiation dose with cardiac events and survival post-chemoradiation therapy (CRT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) after adoption of modern radiation therapy (RT) techniques, stricter cardiac dose constraints, and immune checkpoint inhibitor (ICI) consolidation. METHODS AND MATERIALS: This single-institution, multi-site retrospective study included 335 patients with LA-NSCLC treated with definitive, concurrent CRT between October 2017 and December 2021. All patients were evaluated for ICI consolidation. Planning dose constraints included heart mean dose < 20 Gy (<10 Gy if feasible) and heart volume receiving ≥ 50 Gy (V50Gy) < 25 %. Twenty-one dosimetric parameters for three different cardiac structures (heart, left anterior descending coronary artery [LAD], and left ventricle) were extracted. Primary endpoint was any major adverse cardiac event (MACE) post-CRT, defined as acute coronary syndrome, heart failure, coronary revascularization, or cardiac-related death. Secondary endpoints were: grade ≥ 3 cardiac events (per CTCAE v5.0), overall survival (OS), lung cancer-specific mortality (LCSM), and other-cause mortality (OCM). RESULTS: Median age was 68 years, 139 (41 %) had baseline coronary heart disease, and 225 (67 %) received ICI consolidation. Proton therapy was used in 117 (35 %) and intensity-modulated RT in 199 (59 %). Median LAD V15Gy was 1.4 % (IQR 0-22) and median heart mean dose was 8.7 Gy (IQR 4.6-14.4). Median follow-up was 3.3 years. Two-year cumulative incidence of MACE was 9.5 % for all patients and 14.3 % for those with baseline coronary heart disease. Two-year cumulative incidence of grade ≥ 3 cardiac events was 20.4 %. No cardiac dosimetric parameter was associated with an increased risk of MACE or grade ≥ 3 cardiac events. On multivariable analysis, cardiac dose (LAD V15Gy and heart mean dose) was associated with worse OS, driven by an association with LCSM but not OCM. CONCLUSIONS: With modern RT techniques, stricter cardiac dose constraints, and ICI consolidation, cardiac dose was associated with LCSM but not OCM or cardiac events in patients with LA-NSCLC.
引用
- Yegya-Raman N, Ho Lee S, Friedes C, et al. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation. Radiother Oncol. 2023. PMID: 37972736. doi:10.1016/j.radonc.2023.110005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。